Reducing cross-shareholdings and reviewing the rationale for holding them
First written in FY2023. 1 of 3 entries say "Advanced", first in FY2024-Q3. Latest entry: FY2026.
- FY2026RestatedAnnual report
「At a meeting of the Board of Directors held in December 2025, the company reviewed the rationale and other considerations for listed shares held as of the end of March 2025, conducted a comprehensive review including potential risks, and decided to continue holding 5 shares.」
For cross-shareholdings, the company continues to review the cost of capital, TSR and potential risks annually and maintain a policy of selling holdings whose rationale has weakened. - FY2024-Q3AdvancedAnnual report
「In extraordinary income and expenses, the company recorded a gain on sales of investment securities of ¥1,210 million, mainly from the sale of cross-shareholdings, and a gain on sales of property, plant and equipment of ¥440 million, mainly from the sale of assets of overseas subsidiaries.」
The company recognized a gain on sales of investment securities of ¥1,210 million from the sale of cross-shareholdings. The reduction in holdings following a review of their rationale was also disclosed in the income statement. - FY2023First statedAnnual report
「At a meeting of the Board of Directors held in November 2022, the company reviewed the rationale and other considerations for listed shares held as of the end of March 2022. Based on the results, it sold 4 cross-shareholdings. After comprehensive consideration, including potential risks, it decided to continue holding 7 shares, while continuing to review the appropriateness of those holdings.」
For cross-shareholdings, the company has adopted a policy of conducting annual reviews against the cost of capital and other criteria and disclosed that it sold 4 holdings and continued to hold 7 at a Board of Directors meeting in November 2022.